Acasti Pharma Performance
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
On a scale of 0 to 100, Acasti Pharma holds a performance score of 10. The firm shows a Beta (market volatility) of 0.22, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Acasti Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Acasti Pharma is expected to be smaller as well. Please check Acasti Pharma's coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Acasti Pharma's price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Acasti Pharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Acasti Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 27.9 M |
Acasti |
Acasti Pharma Relative Risk vs. Return Landscape
If you would invest 264.00 in Acasti Pharma on August 29, 2024 and sell it today you would earn a total of 73.00 from holding Acasti Pharma or generate 27.65% return on investment over 90 days. Acasti Pharma is currently generating 0.7016% in daily expected returns and assumes 5.0713% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Acasti, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acasti Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acasti Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acasti Pharma, and traders can use it to determine the average amount a Acasti Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1383
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ACST | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.07 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.7 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Acasti Pharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acasti Pharma by adding it to a well-diversified portfolio.
Acasti Pharma Fundamentals Growth
Acasti Stock prices reflect investors' perceptions of the future prospects and financial health of Acasti Pharma, and Acasti Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acasti Stock performance.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 | |||
| Current Valuation | 11.17 M | |||
| Shares Outstanding | 10.14 M | |||
| Price To Earning | 15.34 X | |||
| Price To Book | 0.58 X | |||
| Price To Sales | 208.39 X | |||
| EBITDA | (11.3 M) | |||
| Cash And Equivalents | 38.39 M | |||
| Cash Per Share | 0.86 X | |||
| Total Debt | 11.56 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 5.86 X | |||
| Cash Flow From Operations | (12.33 M) | |||
| Earnings Per Share | (1.43) X | |||
| Total Asset | 73.3 M | |||
| Retained Earnings | (211.12 M) | |||
| Current Asset | 11.33 M | |||
| Current Liabilities | 1.14 M | |||
About Acasti Pharma Performance
Assessing Acasti Pharma's fundamental ratios provides investors with valuable insights into Acasti Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acasti Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about Acasti Pharma performance evaluation
Checking the ongoing alerts about Acasti Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acasti Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acasti Pharma is now traded under the symbol GRCE. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Acasti Pharma is not yet fully synchronised with the market data | |
| Acasti Pharma is way too risky over 90 days horizon | |
| Acasti Pharma appears to be risky and price may revert if volatility continues | |
| Acasti Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.85 M) with profit before overhead, payroll, taxes, and interest of 120 K. | |
| Acasti Pharma currently holds about 38.39 M in cash with (12.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 38.0% of the company shares are held by company insiders |
- Analyzing Acasti Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acasti Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Acasti Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acasti Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acasti Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acasti Pharma's stock. These opinions can provide insight into Acasti Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| CEOs Directory Screen CEOs from public companies around the world |